Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 24, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 18, 2020 , the Compensation Committee of the Board of Directors approved "inducement" grants to 25 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
  PASADENA, Calif. --(BUSINESS WIRE)--Jul. 9, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020 , at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal third quarter ended June 30, 2020 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 2-4, 2020 June 4 , 2:00 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
- Conference Call and Webcast Today, May 7 at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2020 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2020 Health Care Conference – May 12-14, 2020 May 14 , 11:00 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the retirement of Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 22, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal second quarter ended March 31, 2020 .
View HTML